Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.48 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.48 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.53 |
| ▸ | UBE2T | Q9NPD8 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | MASP2 | O00187 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | THPO | P40225 | 1/20 | 0.41 |
| ▸ | FURIN | P09958 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL415707 | 0.98 | NAPRT (0.55) | LMNANAPRTDGAT1ADRA2AADRA2B | |
| SCHEMBL19047417 | 0.82 | NAPRT (0.52) | LMNANAPRTDGAT1ADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL5013500 | 0.79 | NAPRT (0.64) | NAPRTDGAT1ADRA2AADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3346497 | 0.79 | NAPRT (0.64) | NAPRTDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL17778492 | 0.78 | NAPRT (0.52) | NAPRTDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL388168 | 0.77 | NAPRT (0.67) | NAPRTDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL29524193 | 0.77 | NAPRT (0.67) | NAPRTDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL5353170 | 0.77 | NAPRT (0.55) | NAPRTDGAT1ADRA2AADRA2BADRA2C | |
| SCHEMBL19724261 | 0.77 | DGAT1 (0.59) | LMNANAPRTDGAT1 | |
| SCHEMBL14214692 | 0.76 | DGAT1 (0.50) | NAPRTDGAT1ADRA2AADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112300075-B | 2,4, 5-trisubstituted imidazole compound and preparation method thereof | 阿里生物新材料（常州）有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-112300075-A | 2,4, 5-trisubstituted imidazole compound and preparation method thereof | 阿里生物新材料（常州）有限公司 | 2021-02-02 | — | — | CN | claimed |
| US-20250188053-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| CN-117209508-A | Azaphenothiazine compound and preparation method thereof | 五邑大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-110248932-B | Pyrimidine tricycloalkenone derivatives for ROR γ inhibition and other uses | 里亚塔医药公司 | 2023-03-10 | — | — | CN | disclosed |
| US-20220348549-A1 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2022-11-03 | — | — | US | disclosed |
| CN-112300075-B | 2,4, 5-trisubstituted imidazole compound and preparation method thereof | 阿里生物新材料（常州）有限公司 | 2022-07-15 | — | — | CN | disclosed |
| EP-4021895-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. Hoffmann-La Roche AG (CH) | 2022-07-06 | — | — | EP | disclosed |
| US-20220135534-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | REATA PHARMACEUTICALS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
| US-11292781-B2 | Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses | REATA PHARMACEUTICALS, INC. (US) | 2022-04-05 | — | — | US | disclosed |
| WO-2021037868-A1 | NOVEL QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2021-03-04 | — | — | WO | disclosed |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2016-05-26 | — | — | US | disclosed |
| WO-2015006689-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | UNIVERSITY OF SOUTH ALABAMA (US) | 2015-01-15 | — | — | WO | disclosed |
| EP-2434885-B1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8492392-B2 | Alkoxy tetrahydro-pyridopyrimidine PDE10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-15 | — | — | US | disclosed |
| WO-2010138430-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20060166992-A1 | Heterocyclically substituted imidazotriazines | BAYER HEALTHCARE A G (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-0915879-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 1999-05-19 | — | — | EP | disclosed |
| WO-1998001449-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135534-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | ADRA2A 2046/4885ADRA2B 1438/4885ADRA2C 1249/4885 |
| US-20060166992-A1 | Heterocyclically substituted imidazotriazines | SNCA, PARK7, TPMT | ADRA2A 683/4885ADRA2B 1057/4885ADRA2C 527/4885 |
| US-20120065211-A1 | ALKOXY TETRAHYDRO-PYRIDOPYRIMIDINE PDE10 INHIBITORS | PDE12, PDE4A, PDE5A | ADRA2A 1827/4885ADRA2B 1639/4885ADRA2C 1483/4885 |
| US-20250188053-A1 | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF ROR-GAMMA AND OTHER USES | RORC, RORB, RORA | ADRA2A 2046/4885ADRA2B 1438/4885ADRA2C 1249/4885 |
| US-11292781-B2 | Pyrimidine tricyclic enone derivatives for inhibition of ROR-gamma and other uses | RORC, RORB, RORA | ADRA2A 2046/4885ADRA2B 1438/4885ADRA2C 1249/4885 |
| US-20220348549-A1 | QUINAZOLINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS DISEASE | HAVCR2, RECQL, SLC10A1 | ADRA2A 1423/4885ADRA2B 701/4885ADRA2C 1068/4885 |
| US-20160143912-A1 | TREATMENT AND DIAGNOSIS OF CANCER AND PRECANCEROUS CONDITIONS USING PDE10A INHIBITORS AND METHODS TO MEASURE PDE10A EXPRESSION | PDE4A, PDE7B, PDE2A | ADRA2A 1023/4885ADRA2B 765/4885ADRA2C 1689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.